NewslettersImmunology of Infectious Disease NewsOcrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple SclerosisBy lbeveridge - October 18, 20220183Researchers assessed if serum ocrelizumab concentration measured at time of vaccination could predict the humoral response after SARS-CoV-2 vaccination.[Annals of Neurology]Abstract